RVNC vs. URA

Last updated Jun 4, 2026

RVNC (Revance Therapeutics, Inc.) is a stock, while URA (Global X Uranium ETF) is Commodity Producers Equities fund tracking the Solactive Global Uranium & Nuclear Components Total Return Index.

Performance

RVNC vs. URA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Revance Therapeutics, Inc. (RVNC) and Global X Uranium ETF (URA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

RVNC

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

URA

• 1D: -5.67%
• 1M: -8.00%
• YTD: 17.93%
• 6M: 13.25%
• 1Y: 61.26%
• 3Y*: 39.27%
• 5Y*: 21.39%
• 10Y*: 17.12%

*Multi-year figures are annualized to reflect compound growth (CAGR)

RVNC vs. URA - Yearly Performance Comparison

	2026 (YTD)
RVNC Revance Therapeutics, Inc.	0.00%
URA Global X Uranium ETF	-3.39%

Return for Risk

RVNC vs. URA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

URA

URA Risk / Return Rank: 34
URA Sharpe Ratio Rank: 33
URA Sortino Ratio Rank: 34
URA Omega Ratio Rank: 31
URA Calmar Ratio Rank: 43
URA Martin Ratio Rank: 30

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RVNC vs. URA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Revance Therapeutics, Inc. (RVNC) and Global X Uranium ETF (URA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	RVNC	URA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	1.23	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.49	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.46	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	-0.05	—

Drawdowns

RVNC vs. URA - Drawdown Comparison

The maximum RVNC drawdown since its inception was 0.00%, smaller than the maximum URA drawdown of -93.54%. Use the drawdown chart below to compare losses from any high point for RVNC and URA.

Drawdown Indicators

	RVNC	URA	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-93.54%	+93.54%
Max Drawdown (1Y) Largest decline over 1 year	—	-28.43%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-37.81%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-37.90%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-61.45%	—
Current Drawdown Current decline from peak	0.00%	-42.81%	+42.81%
Average Drawdown Average peak-to-trough decline	0.00%	-75.01%	+75.01%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	13.40%	—

Volatility

Volatility by Period

	RVNC	URA	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	15.94%	—
Volatility (6M) Calculated over the trailing 6-month period	—	38.29%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	50.19%	-50.19%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	43.62%	-43.62%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	37.73%	-37.73%

Dividends

RVNC vs. URA - Dividend Comparison

RVNC has not paid dividends to shareholders, while URA's dividend yield for the trailing twelve months is around 4.14%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
RVNC Revance Therapeutics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
URA Global X Uranium ETF	4.14%	4.88%	2.86%	6.07%	0.76%	5.84%	1.69%	1.66%	0.44%	2.03%	7.28%	1.96%